JP6657105B2 - 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 - Google Patents

発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 Download PDF

Info

Publication number
JP6657105B2
JP6657105B2 JP2016553231A JP2016553231A JP6657105B2 JP 6657105 B2 JP6657105 B2 JP 6657105B2 JP 2016553231 A JP2016553231 A JP 2016553231A JP 2016553231 A JP2016553231 A JP 2016553231A JP 6657105 B2 JP6657105 B2 JP 6657105B2
Authority
JP
Japan
Prior art keywords
gene expression
submodel
sample
value
dlbcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016553231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502686A (ja
JP2017502686A5 (enExample
Inventor
エム． スタウドゥトゥ、ルイズ
エム． スタウドゥトゥ、ルイズ
ダブリュ． ライト、ジョージ
ダブリュ． ライト、ジョージ
ウィリアム スコット、デービッド
ウィリアム スコット、デービッド
エム． コンノルス、ジョセフ
エム． コンノルス、ジョセフ
ディー． ガスコイン、ランディー
ディー． ガスコイン、ランディー
リムスザ、リサ
グエリ、エリアス カンポ
グエリ、エリアス カンポ
タバス、レイモンド
シー． グレイナー、ティモシー
シー． グレイナー、ティモシー
ロバート クック、ジェームズ
ロバート クック、ジェームズ
フ、カイ
ミカエル ウィリアムズ、ポール
ミカエル ウィリアムズ、ポール
リヒ、チヒ−ジアン
エス． ジャフィー、イライン
エス． ジャフィー、イライン
エム． ブラジエル、リタ
エム． ブラジエル、リタ
ロセンワルド、アンドレアス
ビー． スメランド、エルレンド
ビー． スメランド、エルレンド
シー． チャン、ウィング
シー． チャン、ウィング
オット、ゲルマン
デラビエ、ジャン
ウエイセンバーガー、デニス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Government of the United States of America
Original Assignee
Cleveland Clinic Foundation
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation, Government of the United States of America filed Critical Cleveland Clinic Foundation
Publication of JP2017502686A publication Critical patent/JP2017502686A/ja
Publication of JP2017502686A5 publication Critical patent/JP2017502686A5/ja
Application granted granted Critical
Publication of JP6657105B2 publication Critical patent/JP6657105B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016553231A 2013-11-06 2014-11-05 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 Active JP6657105B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361900553P 2013-11-06 2013-11-06
US61/900,553 2013-11-06
PCT/US2014/064161 WO2015069790A1 (en) 2013-11-06 2014-11-05 Method for subtyping lymphoma types by means expression profiling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020018323A Division JP7016129B2 (ja) 2013-11-06 2020-02-05 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法

Publications (3)

Publication Number Publication Date
JP2017502686A JP2017502686A (ja) 2017-01-26
JP2017502686A5 JP2017502686A5 (enExample) 2017-12-14
JP6657105B2 true JP6657105B2 (ja) 2020-03-04

Family

ID=51987470

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016553231A Active JP6657105B2 (ja) 2013-11-06 2014-11-05 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法
JP2020018323A Active JP7016129B2 (ja) 2013-11-06 2020-02-05 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020018323A Active JP7016129B2 (ja) 2013-11-06 2020-02-05 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法

Country Status (9)

Country Link
US (2) US10607717B2 (enExample)
EP (2) EP3066215B1 (enExample)
JP (2) JP6657105B2 (enExample)
KR (1) KR102357699B1 (enExample)
CN (1) CN106232831B (enExample)
AU (1) AU2014346788B8 (enExample)
CA (1) CA2929826C (enExample)
ES (2) ES2923942T3 (enExample)
WO (1) WO2015069790A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
US10609336B2 (en) * 2015-04-16 2020-03-31 Offender Smartphone Monitoring, LLC Monitoring process
CN109516981B (zh) 2015-07-13 2019-10-22 大连万春布林医药有限公司 普那布林组合物
AU2016331058B2 (en) 2015-09-29 2022-04-07 Htg Molecular Diagnostics, Inc. Methods for subtyping diffuse large b-cell lymphoma (dlbcl)
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
WO2017184861A1 (en) 2016-04-20 2017-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Evaluation of mantle cell lymphoma and methods related thereto
CA3023841C (en) 2016-05-13 2021-10-19 F. Hoffmann-La Roche Ag Methods and compositions for classifying dlbcl
KR20240091084A (ko) 2016-06-06 2024-06-21 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
WO2018089442A2 (en) * 2016-11-09 2018-05-17 Intel IP Corporation Ue and devices for detach handling
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
IL268305B2 (en) 2017-02-01 2024-08-01 Beyondspring Pharmaceuticals Inc Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced
EP3638814B8 (en) 2017-06-14 2023-06-21 The United States of America, as Represented by The Secretary, Department of Health and Human Services Method for determining lymphoma type
CN111032692A (zh) * 2017-08-08 2020-04-17 豪夫迈·罗氏有限公司 一种dlbcl患者亚组的奥滨尤妥珠单抗治疗
JP7517983B2 (ja) * 2017-11-20 2024-07-17 ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク 非常に低レベルのｃｄ１９を発現する骨髄腫細胞を除去するｃｄ１９ｃａｒｔ細胞
JP7365052B2 (ja) 2017-12-01 2023-10-19 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
US11414661B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
KR102834361B1 (ko) 2017-12-01 2025-07-17 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도
WO2019105418A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
US11414665B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
CA3087106A1 (en) 2017-12-29 2019-07-04 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
WO2020028563A1 (en) * 2018-08-01 2020-02-06 Genentech, Inc. Prediction and characterization of dlbcl cell of origin subtypes
JP2021533800A (ja) 2018-08-21 2021-12-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. 核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用
CN111655297A (zh) 2018-09-30 2020-09-11 苏州瑞博生物技术有限公司 一种siRNA缀合物及其制备方法和用途
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3867404B1 (en) * 2018-10-15 2025-09-17 Provincial Health Services Authority Gene expression profiles for b-cell lymphoma and uses thereof
CN113661253B (zh) * 2018-11-14 2024-03-12 大连万春布林医药有限公司 微管蛋白结合剂治疗癌症的方法
KR20210144863A (ko) * 2019-03-28 2021-11-30 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) B-세포 비-호지킨 림프종의 분류
CN111850114A (zh) * 2019-04-25 2020-10-30 上海交通大学医学院附属瑞金医院 一组用于评估弥漫大b细胞淋巴瘤分子分型的基因群，其试剂盒及分析方法
CN113614230B (zh) * 2019-05-22 2024-04-09 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
WO2021013805A1 (en) * 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag Systems and methods for cell of origin determination from variant calling data
EP4013494A1 (en) 2019-08-12 2022-06-22 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
CN111621565B (zh) * 2020-05-07 2023-12-15 杭州可帮基因科技有限公司 弥漫性大b细胞淋巴瘤分子分型试剂盒及分型装置
CN111785370B (zh) * 2020-07-01 2024-05-17 医渡云（北京）技术有限公司 病历数据处理方法及装置、计算机存储介质、电子设备
BR112023000125A2 (pt) * 2020-07-08 2023-04-11 Dayton Therapeutics Ag Satraplatina para uso no tratamento de neoplasias linfoides
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法
CN113186289B (zh) * 2021-05-12 2023-02-24 清华大学深圳国际研究生院 lncRNA在肾癌尿液筛查和肾癌治疗中的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5252743A (en) 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
DE69132905T2 (de) 1990-12-06 2002-08-01 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Detektion von Nukleinsäuresequenzen
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
AU675054B2 (en) 1991-11-22 1997-01-23 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US5550215A (en) 1991-11-22 1996-08-27 Holmes; Christopher P. Polymer reversal on solid surfaces
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US6090555A (en) 1997-12-11 2000-07-18 Affymetrix, Inc. Scanned image alignment systems and methods
DE69503126T2 (de) 1994-05-05 1998-11-12 Beckman Instruments Inc Repetitive oligonukleotide matrix
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
JP2000512744A (ja) 1996-05-16 2000-09-26 アフィメトリックス，インコーポレイテッド 標識材料を検出するシステムおよび方法
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US5936324A (en) 1998-03-30 1999-08-10 Genetic Microsystems Inc. Moving magnet scanner
US6020198A (en) 1998-09-25 2000-02-01 Isis Pharmaceuticals Inc. Antisense modulation of RIP-1 expression
US7105293B2 (en) 2000-09-19 2006-09-12 Whitehead Institute For Biomedical Research Genetic markers for tumors
US20030194701A1 (en) 2000-11-20 2003-10-16 Golub Todd R. Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
EP1436283B1 (en) 2001-09-21 2008-01-23 Boryung Pharmaceutical Co., Ltd. Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
MXPA05005923A (es) 2002-12-06 2005-09-21 Millennium Pharm Inc Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
JP4607879B2 (ja) 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
US7711492B2 (en) 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
US20110152115A1 (en) 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
ATE514434T1 (de) 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
EP1805197A1 (en) 2004-09-27 2007-07-11 Med Biogene Inc Hematological cancer profiling system
WO2006110264A2 (en) 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
BRPI0820707A2 (pt) * 2007-11-07 2015-06-16 Genentech Inc Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40
US20110195426A1 (en) 2009-07-16 2011-08-11 The General Hospital Corporation Nucleic acids analysis
EP2604704B1 (en) 2008-02-01 2018-10-03 The General Hospital Corporation Use of microvesicles in diagnosis and prognosis of brain tumor
CA2726811C (en) 2008-06-06 2019-11-26 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Survival predictor for diffuse large b cell lymphoma
ES2352777B1 (es) 2009-07-31 2012-01-23 Hospital Clinic De Barcelona Metodo y kit para el pronostico del linfoma de celulas del manto
CA2778953C (en) * 2009-11-13 2020-01-14 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
WO2011097476A1 (en) 2010-02-04 2011-08-11 Indiana University Research And Technology Corporation 4-protein biomarker panel for the diagnosis of lymphoma from biospecimen
EP2569335B1 (en) * 2010-05-14 2018-08-22 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
NZ604040A (en) * 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
US20120258878A1 (en) 2010-08-04 2012-10-11 Med Biogene Inc. Prognostic gene signatures for non-small cell lung cancer
CN103688176A (zh) * 2011-04-29 2014-03-26 细胞基因公司 利用cereblon作为预报因子治疗癌和炎性疾病的方法
EP2788535A4 (en) 2011-12-09 2015-07-29 British Columbia Cancer Agency PREDICTION OF A PROGNOSIS IN CLASSIC HODGKIN LYMPHOMA
US9493775B2 (en) * 2012-02-10 2016-11-15 Whitehead Institute For Biomedical Research Inhibition of the glycine cleavage system for treatment of cancer
US9803245B2 (en) 2012-03-14 2017-10-31 University Health Network Signature for predicting clinical outcome in human HER2+ breast cancer
WO2013188600A1 (en) 2012-06-12 2013-12-19 Washington University Copy number aberration driven endocrine response gene signature
WO2014197936A1 (en) 2013-06-14 2014-12-18 The State Of Queensland Acting Through Its Department Of Health Biomarkers and use thereof in identification of b-cell lymphoproliferative disorders
EA201691144A1 (ru) 2013-12-06 2016-11-30 Селджин Корпорейшн Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка
CN106973568B (zh) 2014-10-08 2021-07-23 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途

Also Published As

Publication number Publication date
AU2014346788B8 (en) 2021-01-28
WO2015069790A1 (en) 2015-05-14
CA2929826C (en) 2022-08-16
KR102357699B1 (ko) 2022-02-04
CA2929826A1 (en) 2015-05-14
JP2020078323A (ja) 2020-05-28
EP3594359A1 (en) 2020-01-15
ES2738289T3 (es) 2020-01-21
US20160283653A1 (en) 2016-09-29
EP3594359B1 (en) 2022-05-18
EP3066215A1 (en) 2016-09-14
CN106232831A (zh) 2016-12-14
ES2923942T3 (es) 2022-10-03
US11574704B2 (en) 2023-02-07
AU2014346788A8 (en) 2016-06-16
WO2015069790A9 (en) 2016-06-02
CN106232831B (zh) 2021-02-26
EP3066215B1 (en) 2019-04-24
JP2017502686A (ja) 2017-01-26
US20200143906A1 (en) 2020-05-07
JP7016129B2 (ja) 2022-02-04
US10607717B2 (en) 2020-03-31
KR20160127713A (ko) 2016-11-04
AU2014346788B2 (en) 2020-09-24
AU2014346788A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
JP7016129B2 (ja) 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法
US10697975B2 (en) Methods for identifying, diagnosing, and predicting survival of lymphomas
CN102346816A (zh) 用于鉴别鼻咽癌中的预后型亚类的基因表达谱
CA2939539A1 (en) Prostate cancer survival and recurrence
EP2036987A1 (en) Molecular markers for tumor cell content in tissue samples
EP2307570A1 (en) Molecular signature of liver tumor grade and use to evaluate prognosis and therapeutic regimen
AU2020245086A1 (en) Classification of B-Cell non-Hodgkin Lymphomas
AU2021291133A1 (en) Methods for detecting and predicting cancer and/or CIN3
JP7075896B2 (ja) マントル細胞リンパ腫の評価及びそれに関連する方法
EP3638814B1 (en) Method for determining lymphoma type
AU2007277142B2 (en) Methods for identifying, diagnosing, and predicting survival of lymphomas
Winokur Molecular markers in breast cancer: current practice and future possibilities
HK1228459B (en) Method for subtyping lymphoma types by means of expression profiling
HK1228459A1 (en) Method for subtyping lymphoma types by means of expression profiling

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191008

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200205

R150 Certificate of patent or registration of utility model

Ref document number: 6657105

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250